T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
AuthorsChapuis, Aude G
Egan, Daniel N
Schmitt, Thomas M
McAfee, Megan S
Paulson, Kelly G
Ragnarsson, Gunnar B
Yeung, Cecilia C
Nguyen, Hieu N
Kropp, Lara A
McElrath, M Juliana
Gooley, Ted A
Greenberg, Philip D
MetadataShow full item record
CitationT cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant. 2019, 25(7):1064-1072 Nat Med
AbstractRelapse after allogeneic hematopoietic cell transplantation (HCT) is the leading cause of death in patients with acute myeloid leukemia (AML) entering HCT with poor-risk features1-3. When HCT does produce prolonged relapse-free survival, it commonly reflects graft-versus-leukemia effects mediated by donor T cells reactive with antigens on leukemic cells4. As graft T cells have not been selected for leukemia specificity and frequently recognize proteins expressed by many normal host tissues, graft-versus-leukemia effects are often accompanied by morbidity and mortality from graft-versus-host disease5. Thus, AML relapse risk might be more effectively reduced with T cells expressing receptors (TCRs) that target selected AML antigens6. We therefore isolated a high-affinity Wilms' Tumor Antigen 1-specific TCR (TCRC4) from HLA-A2+ normal donor repertoires, inserted TCRC4 into Epstein-Bar virus-specific donor CD8+ T cells (TTCR-C4) to minimize graft-versus-host disease risk and enhance transferred T cell survival7,8, and infused these cells prophylactically post-HCT into 12 patients ( NCT01640301 ). Relapse-free survival was 100% at a median of 44 months following infusion, while a concurrent comparative group of 88 patients with similar risk AML had 54% relapse-free survival (P = 0.002). TTCR-C4 maintained TCRC4 expression, persisted long-term and were polyfunctional. This strategy appears promising for preventing AML recurrence in individuals at increased risk of post-HCT relapse.
DescriptionTo access publisher's full text version of this article click on the hyperlink below
- Wilms' tumor gene 1 is an independent prognostic factor for pediatric acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation.
- Authors: Deng DX, Wen JJ, Cheng YF, Zhang XH, Xu LP, Wang Y, Yan CH, Chen YH, Chen H, Han W, Wang FR, Wang JZ, Qin YZ, Liu KY, Huang XJ, Zhao XS, Mo XD
- Issue date: 2021 Mar 19
- Induction of Immune Response after Allogeneic Wilms' Tumor 1 Dendritic Cell Vaccination and Donor Lymphocyte Infusion in Patients with Hematologic Malignancies and Post-Transplantation Relapse.
- Authors: Shah NN, Loeb DM, Khuu H, Stroncek D, Ariyo T, Raffeld M, Delbrook C, Mackall CL, Wayne AS, Fry TJ
- Issue date: 2016 Dec
- Post-Transplant Cyclophosphamide Combined with Anti-Thymocyte Globulin as Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome.
- Authors: Alanazi W, Chen S, Lipton JH, Kim DD, Viswabandya A, Kumar R, Lam W, Law AD, Al-Shaibani Z, Mattsson J, Michelis FV
- Issue date: 2021
- Wilms' tumor gene 1 transcript levels in leukapheresis of peripheral blood hematopoietic cells predict relapse risk in patients autografted for acute myeloid leukemia.
- Authors: Messina C, Candoni A, Carrabba MG, Tresoldi C, Sala E, Tassara M, Crippa A, Peccatori J, Assanelli A, Gattillo S, Bellio L, Fanin R, Ciceri F, Bernardi M
- Issue date: 2014 Oct
- Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
- Authors: Takenaka K, Nishida T, Asano-Mori Y, Oshima K, Ohashi K, Mori T, Kanamori H, Miyamura K, Kato C, Kobayashi N, Uchida N, Nakamae H, Ichinohe T, Morishima Y, Suzuki R, Yamaguchi T, Fukuda T
- Issue date: 2015 Nov